TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
D.Western Therapeutics Institute ( (JP:4576) ) has provided an update.
D.Western Therapeutics Institute, Inc. has completed the final observation phase of its domestic phase II clinical trial for the regenerative medical cell product DWR-2206, developed in collaboration with ActualEyes Inc. The trial, aimed at evaluating the safety and efficacy of DWR-2206 for treating bullous keratopathy, reported no critical adverse events and noted improvements in visual acuity. The company is now preparing for a phase III clinical trial scheduled for fiscal 2026, marking a significant milestone in the development of this innovative treatment. This progress aligns with the company’s plans and is not expected to impact the earnings forecast for the fiscal year ending December 2025.
The most recent analyst rating on (JP:4576) stock is a Hold with a Yen98.00 price target. To see the full list of analyst forecasts on D.Western Therapeutics Institute stock, see the JP:4576 Stock Forecast page.
More about D.Western Therapeutics Institute
D.Western Therapeutics Institute, Inc. operates in the biotechnology industry, focusing on the development of regenerative medical products. The company is known for its work on innovative treatments, particularly in collaboration with partners like ActualEyes Inc., to address conditions such as bullous keratopathy.
Average Trading Volume: 4,407,378
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen5.58B
See more data about 4576 stock on TipRanks’ Stock Analysis page.